October 25, 2016
Curetis Announces Positive Top Line Data from U.S. FDA Trial – Primary endpoint for Unyvero LRT product for lower respiratory tract infections shows overall weighted average […]
September 7, 2016
Curetis Acquires Patents and Rights to Genetic Antibiotic Resistance and Susceptibility (GEAR) Database and Know-How from Siemens – Agreement gives Curetis worldwide rights to database and […]
September 6, 2016
Curetis to Launch Next Generation CE-IVD Unyvero Implant and Tissue Infection Application Cartridge – Launch follows successful completion of CE Performance Evaluation Study – ITI now […]
July 5, 2016
Curetis Appoints Christopher M. Bernard as Chief Executive Officer of Newly-Formed U.S. Subsidiary – Former Chief Commercial Officer of Epic Sciences brings valuable experience in sales, […]
June 28, 2016
Curetis Completes Sample Enrollment in Unyvero U.S. FDA Trial in Lower Respiratory Tract Infections – Last patient enrolled in prospective arm of IVD trial – More […]
June 17, 2016
Jun 16, 2016 | NEW YORK (GenomeWeb) – Curetis said today that it has received the CE-IVD mark for its Unyvero BCU Blood Culture Application Cartridge […]
May 20, 2016
Curetis Publishes First Quarter 2016 Business and Financial Update – Worldwide commercial expansion and US FDA trial on track – Installed base of Unyvero Analyzers increased […]
April 13, 2016
-First and only blood-based colorectal cancer screening test approved by the FDA -Innovative, convenient and effective screening option for millions of eligible Americans -Commercialization initiated with […]
March 31, 2016
Seattle-based Clinical Research Organization is Awarded a National Cancer Institute (NCI) Contract for Oncology Biospecimen Collection SEATTLE, March 30, 2016 Global BioClinical (GBC), http://www.globalbioclinical.com, is pleased to […]
